Cepheid Boasts 35 Percent Revenue Growth for Q3 | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its third-quarter revenues rose 35 percent year over year, and the firm cut its net loss by more than two-thirds.

The Sunnyvale, Calif.-based molecular diagnostics firm brought in total revenues of $56.1 million for the three-month period ended Sept. 30, compared to $41.6 million for Q3 2009. It surpassed analysts' consensus estimate of $52.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.